D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

In recent years, the therapeutic application of Janus kinase (JAK) inhibitors in dermatology-particularly in the management of atopic dermatitis-has expanded markedly. This bibliometric study aimed to characterize research themes, evaluate the scientific productivity of authors and countries, and highlight emerging areas that may guide future research in this field over the past decade.

The bibliometric analysis of JAK inhibitors in atopic dermatitis from 2015 to 2024 was conducted using the Web of Science Core Collection (WoSCC) database as the search data source. Bibliometric analyses and data visualizations were performed using CiteSpace, VOSviewer, and the Bibliometrix package in R.

We included 1413 studies in our analysis. The cluster plot divided all keywords into 9 categories. Pruritus and alopecia areata were the most frequently co-occurring keywords alongside atopic dermatitis, while delgocitinib and abrocitinib were the most frequently investigated JAK inhibitors. The United States produced the highest number of publications over the past decade. Mount Sinai and the University of California System showed notable post-2020 growth, reaching ~190 and ~145 publications by 2025, respectively, reflecting growing academic engagement. Emma Guttman-Yassky emerged as both the most influential and the most cited author in the field, as reflected by citation impact, followed by Jonathan Silverberg.

Janus kinase (JAK) inhibitors represent one of the most effective and trending therapeutic classes in atopic dermatitis. These agents are not only highly effective for atopic dermatitis but also show promising efficacy in other dermatologic conditions, such as alopecia areata.